These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 30260412)

  • 1. Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: an open-label Phase IIIb/IV study (PROFILE).
    Högenauer C; Mahida Y; Stallmach A; Marteau P; Rydzewska G; Ivashkin V; Gargalianos-Kakolyris P; Michon I; Adomakoh N; Georgopali A; Tretter R; Karas A; Reinisch W
    J Antimicrob Chemother; 2018 Dec; 73(12):3430-3441. PubMed ID: 30260412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
    Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
    Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.
    Cornely OA; Vehreschild MJGT; Adomakoh N; Georgopali A; Karas A; Kazeem G; Guery B
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1187-1194. PubMed ID: 30911926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE).
    Vehreschild MJGT; Taori S; Goldenberg SD; Thalhammer F; Bouza E; van Oene J; Wetherill G; Georgopali A
    Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2097-2106. PubMed ID: 30099637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile-Associated Diarrhea: A Phase 2a Multicenter Clinical Trial.
    O'Gorman MA; Michaels MG; Kaplan SL; Otley A; Kociolek LK; Hoffenberg EJ; Kim KS; Nachman S; Pfefferkorn MD; Sentongo T; Sullivan JE; Sears P
    J Pediatric Infect Dis Soc; 2018 Aug; 7(3):210-218. PubMed ID: 28575523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial.
    Guery B; Georgopali A; Karas A; Kazeem G; Michon I; Wilcox MH; Cornely OA
    J Antimicrob Chemother; 2020 Apr; 75(4):1014-1018. PubMed ID: 31960058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥60 years (EXTEND): analysis of cost-effectiveness.
    Cornely OA; Watt M; McCrea C; Goldenberg SD; De Nigris E
    J Antimicrob Chemother; 2018 Sep; 73(9):2529-2539. PubMed ID: 29800295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.
    Guery B; Menichetti F; Anttila VJ; Adomakoh N; Aguado JM; Bisnauthsing K; Georgopali A; Goldenberg SD; Karas A; Kazeem G; Longshaw C; Palacios-Fabrega JA; Cornely OA; Vehreschild MJGT;
    Lancet Infect Dis; 2018 Mar; 18(3):296-307. PubMed ID: 29273269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplant.
    Prohaska L; Mahmoudjafari Z; Shune L; Singh A; Lin T; Abhyankar S; Ganguly S; Grauer D; McGuirk J; Clough L
    Hematol Oncol Stem Cell Ther; 2018 Dec; 11(4):233-240. PubMed ID: 29928848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.
    Sears P; Crook DW; Louie TJ; Miller MA; Weiss K
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S116-20. PubMed ID: 22752859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes With Fidaxomicin Therapy in Clostridium difficile Infection.
    Spiceland CM; Khanna S; Pardi DS
    J Clin Gastroenterol; 2018 Feb; 52(2):151-154. PubMed ID: 28009682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Crawford T; Huesgen E; Danziger L
    Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
    Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
    J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model.
    Chilton CH; Crowther GS; Todhunter SL; Ashwin H; Longshaw CM; Karas A; Wilcox MH
    J Antimicrob Chemother; 2015 Sep; 70(9):2598-607. PubMed ID: 26078392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection.
    Gehin M; Desnica B; Dingemanse J
    Int J Antimicrob Agents; 2015 Nov; 46(5):576-81. PubMed ID: 26419191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain.
    Rubio-Terrés C; Aguado JM; Almirante B; Cobo J; Grau S; Salavert M; González Antona Sánchez E; López Gutiérrez C; Rubio-Rodríguez D
    Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1105-1111. PubMed ID: 30989419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.